Methylene Blue's Century-Long Journey: From Dye to Potential Alzheimer's Hope

Methylene blue, a synthetic dye first created in 1876, has long been used in medicine for tasks like tracing urinary tracts or detecting lymphatic nodes. Over the decades, its applications have expanded beyond surgery and diagnostics, with researchers exploring its potential in treating rare blood disorders and even neurodegenerative diseases like Alzheimer's disease.

The compound was originally developed by German chemist Heinrich Caro. By 1886, scientists discovered it could stain parasitic cells, aiding in the identification of malaria. Later, it became a treatment for methemoglobinemia, a condition where red blood cells struggle to carry oxygen.

Recent studies suggest methylene blue might offer cognitive benefits. In elderly patients, it showed modest, short-term improvements in mental function after surgery. Researchers believe this effect comes from its ability to enhance mitochondrial oxygen use, potentially increasing energy and alertness. The dye may also block monoamine oxidase, raising serotonin and dopamine levels in the brain.

Some small-scale trials have explored its use in Alzheimer's disease. A Phase 2 extension study, completed around 2021 by TauRx Therapeutics, tested a related compound (LMTX) in earlier-stage patients but found no clear benefit for advanced cases. Larger, systematic trials for late-stage Alzheimer's remain absent, though newer studies—like a Phase 2/3 trial launched in 2024—are now targeting mild-to-moderate stages.

Despite its potential, methylene blue carries risks. It can trigger serotonin syndrome or cause acute hemolytic anemia in individuals with G6PD deficiency. Outside clinical use, some biohackers promote it as a cognitive enhancer, though evidence for such claims remains limited.

Methylene blue's medical journey spans over a century, from surgical dye to experimental Alzheimer's treatment. While early findings hint at cognitive and metabolic benefits, its risks and inconsistent results in large-scale trials highlight the need for further research. For now, its approved uses remain focused on diagnostics and specific blood disorders.